内皮素-1：肺动脉高压的介质？ - Suppr

Endothelin-1: a mediator of pulmonary hypertension?

作者信息

MacLean M R

机构信息

Division of Neuroscience and Biomedical Systems, Pulmonary Research Group, Glasgow, G12 8QQ, UK.

出版信息

Pulm Pharmacol Ther. 1998 Apr-Jun;11(2-3):125-32. doi: 10.1006/pupt.1998.0126.

DOI:10.1006/pupt.1998.0126

PMID:9918744

Abstract

摘要

相似文献

Endothelin-1: a mediator of pulmonary hypertension?

Pulm Pharmacol Ther. 1998 Apr-Jun;11(2-3):125-32. doi: 10.1006/pupt.1998.0126.

Endothelin-1: an interesting peptide or an important mediator in pulmonary diseases?

Pulm Pharmacol Ther. 1998 Apr-Jun;11(2-3):141-6. doi: 10.1006/pupt.1998.0128.

Influence of applied tension and nitric oxide on responses to endothelins in rat pulmonary resistance arteries: effect of chronic hypoxia.

Br J Pharmacol. 1998 Mar;123(5):991-9. doi: 10.1038/sj.bjp.0701682.

Endothelin-1 and the pulmonary vascular response to altitude: a new therapeutic target?

Circulation. 2006 Sep 26;114(13):1350-1. doi: 10.1161/CIRCULATIONAHA.106.650432.

Interrelation between nitric oxide and endothelin-1 in an experimental acute hypoxia in rats and its intervention.

Chin Med J (Engl). 1999 Apr;112(4):363-5.

Pulmonary hypertension, left ventricular dysfunction and plasma serotonin: commentary on Deuchar et al.

Br J Pharmacol. 2002 Nov;137(6):937-8; author reply 938. doi: 10.1038/sj.bjp.0704947.

[Endothelin].

Nihon Rinsho. 2006 Jul;64 Suppl 5:112-6.

Endothelin receptors mediating contraction of rat and human pulmonary resistance arteries: effect of chronic hypoxia in the rat.

Br J Pharmacol. 1998 Apr;123(8):1621-30. doi: 10.1038/sj.bjp.0701785.

Endothelin in the pulmonary circulation with special reference to hypoxic pulmonary vasoconstriction.

Scand Cardiovasc J Suppl. 1997;46:1-40.

Endothelin, the bad actor in the play: a marker or mediator of cardiovascular disease.

J Am Coll Cardiol. 1999 Mar 15;33(4):939-42. doi: 10.1016/s0735-1097(98)00662-7.

引用本文的文献

Drug repurposing-a promising approach for patients with angina but non-obstructive coronary artery disease (ANOCA).

Front Cardiovasc Med. 2023 Jun 16;10:1156456. doi: 10.3389/fcvm.2023.1156456. eCollection 2023.

Macitentan for the treatment of pulmonary arterial hypertension.

Vasc Health Risk Manag. 2014 Nov 25;10:665-73. doi: 10.2147/VHRM.S33904. eCollection 2014.

Combined use of ursodeoxycholic acid and bosentan prevents liver toxicity caused by endothelin receptor antagonist bosentan monotherapy: two case reports.

J Med Case Rep. 2014 Jul 11;8:250. doi: 10.1186/1752-1947-8-250.

Pulmonary arterial hypertension: classification, diagnosis and contemporary management.

Postgrad Med J. 2006 Nov;82(973):717-22. doi: 10.1136/pgmj.2006.044941.

Response to bosentan in children with pulmonary hypertension.

Heart. 2006 May;92(5):664-70. doi: 10.1136/hrt.2005.072314. Epub 2005 Oct 10.

Pulmonary hypertension secondary to left ventricular dysfunction: the role of nitric oxide and endothelin-1 in the control of pulmonary vascular tone.

Br J Pharmacol. 2002 Feb;135(4):1060-8. doi: 10.1038/sj.bjp.0704529.

Regional modulation of cyclic nucleotides by endothelin-1 in rat pulmonary arteries: direct activation of G(i)2-protein in the main pulmonary artery.

Br J Pharmacol. 2000 Mar;129(5):1042-8. doi: 10.1038/sj.bjp.0703153.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Endothelin-1: a mediator of pulmonary hypertension?

作者信息

机构信息

出版信息

相似文献

引用本文的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

相似文献

引用本文的文献